NCT03560934

Tetrahydrocannabinol (THC) and Sleep

Effect of Tetrahydrocannabinol (THC) on Sleep in Humans

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Oregon Health and Science University · Academic / Other
• Sex: All
• Age: 21 Years – 34 Years
• Healthy volunteers: Accepted

Summary

The investigators will test the effects of 10-60mg dronabinol (oral THC) on sleep in non-frequent and frequent cannabis users.

Detailed description

The investigators plan to test the effects of 10-60 mg dronabinol (oral THC) on subjective (surveys) and objective (polysomnographically scored (PSG)) sleep in non-frequent and frequent cannabis users following an acclimation and baseline night of sleep. The mornings after baseline sleep and dronabinol administration, cognitive performance will also be measured and participants may also perform morning typical behaviors such as change in posture (getting out of bed/tilt test) and mild intensity physical activity. This pilot study is in healthy young adults without a history of chronic disease.

Conditions

• Sleep
• THC
• Marijuana
• Cannabis

Interventions

Type	Name	Description
DRUG	Dronabinol	Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.

Timeline

• Start date: 2018-09-01
• Primary completion: 2021-09-19
• Completion: 2025-12-31
• First posted: 2018-06-18
• Last updated: 2026-02-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study